We recently published Trending Analyst Calls: 10 Stocks to Buy and Sell. Biotechnology ETF (NASDAQ:IBB) is one of the trending analyst calls.

Jason Snipe, Founder and CIO of Odyssey Capital Advisors, said in a recent program on CNBC that he’s investing in IBB. Here’s why:

“But this is a subsector that’s been under the mat for quite some time. So it’s nice to see some price action there. So couple things for me. I think one, big pharma, they really need to rebuild their pipeline. So I think there’s going to be some M&A operating in the biotech space and I think that’s going to benefit the iShares Biotechnology ETF (NASDAQ:IBB) and especially some of those smaller names. And I think part of it is the macro deal flow will kind of come back online in that space and I just feel like the IBB will be representative of what’s going to happen.”

Mila Supinskaya Glashchenko/Shutterstock.com

While we acknowledge the potential of IBB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.